Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Evaluating Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) as a novel drug target in Head and Neck Cancer
EF 2021-22
Résumé
Head and Neck Squamous Cell Carcinoma (HNSCC) is one of the deadliest and most prevalent cancers with rising incidence. The treatment options are non-selective and associated with toxicities and other adverse effects, thus highlighting the need for novel therapeutic strategies. CRISPR screening has been widely used to identify genetic vulnerabilities in cancer cell lines. However, these in vitro models lack the tumour microenvironment and do not fully capture the intricate biology of tumours. To address this issue, our group has established HNSCC mouse models that integrate multiplexed in vivo CRISPR/Cas9 mutagenesis to test hundreds of genes in a single mouse within a couple of weeks. To inactivate candidate cancer genes in the oral cavity and skin of mice, highly concentrated CRISPR/Cas9 lentiviruses are being delivered to the single-layer surface ectoderm of living mouse embryos via ultrasound-guided microinjections. Our first in vivo CRISPR screen, performed directly in the epithelium of tumour-prone mice, identified Insulin-like growth factor binding protein 3 (IGFBP3) as a top hit essential for the selective proliferation of transformed epithelial cells. In clinical datasets, IGFBP3 is amplified/gained in ~ 39% of HNSCC patients, and increased mRNA levels correlate with poorer survival. My project aims to combine in vivo CRISPR gene editing in mouse models of HNSCC and functional genomic experimentation in patient-derived HNSCC xenografts to further characterize the oncogenic function of IGFBP3 in HNSCC and delineate its molecular mechanism of action. Successful completion of this project will contribute to novel targeted therapeutics of HNSCC and highlight the potential of in vivo drop-out screens to detect novel, biologically relevant cancer drug targets.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
466615
Name
Fotiadou Iosifina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) as a novel drug target in Head and Neck Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Research; Cell Signalling; Crispr Editing; Functional Genomics; Head And Neck Squamous Cell Carcinoma; In Vivo Crispr Drop-Out Screening; In-Utero Lentiviral Microinjection Delivery Method; Insulin-Like Growth Factor Binding Proteins; Mouse Models Of Cancer; Oncogenes
Abstract
Head and Neck Squamous Cell Carcinoma (HNSCC) is one of the deadliest and most prevalent cancers with rising incidence. The treatment options are non-selective and associated with toxicities and other adverse effects, thus highlighting the need for novel therapeutic strategies. CRISPR screening has been widely used to identify genetic vulnerabilities in cancer cell lines. However, these in vitro models lack the tumour microenvironment and do not fully capture the intricate biology of tumours. To address this issue, our group has established HNSCC mouse models that integrate multiplexed in vivo CRISPR/Cas9 mutagenesis to test hundreds of genes in a single mouse within a couple of weeks. To inactivate candidate cancer genes in the oral cavity and skin of mice, highly concentrated CRISPR/Cas9 lentiviruses are being delivered to the single-layer surface ectoderm of living mouse embryos via ultrasound-guided microinjections. Our first in vivo CRISPR screen, performed directly in the epithelium of tumour-prone mice, identified Insulin-like growth factor binding protein 3 (IGFBP3) as a top hit essential for the selective proliferation of transformed epithelial cells. In clinical datasets, IGFBP3 is amplified/gained in ~ 39% of HNSCC patients, and increased mRNA levels correlate with poorer survival. My project aims to combine in vivo CRISPR gene editing in mouse models of HNSCC and functional genomic experimentation in patient-derived HNSCC xenografts to further characterize the oncogenic function of IGFBP3 in HNSCC and delineate its molecular mechanism of action. Successful completion of this project will contribute to novel targeted therapeutics of HNSCC and highlight the potential of in vivo drop-out screens to detect novel, biologically relevant cancer drug targets.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fotiadou, Iosifina
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~